OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights

What happened

OmniAb reported third-quarter 2026 revenue of $4.0 million, up from $2.2 million a year earlier, driven mainly by service revenue and xPloration revenue. The company also reported nine-month results, partner program progress, and raised its 2026 revenue guidance and cash outlook.

Confirmed

Global impact / market context

Higher revenue from services and instrument sales suggests OmniAb is converting its discovery technology into recurring customer payments. Raising guidance signals management expects the improved trend to continue, which matters for investors judging whether the business can fund operations and grow without heavy new spending.

Analyst inference

OmniAb's model relies on licensing and partnered programs that can produce milestone and royalty payments, which are lumpy and uncertain. The quarter's growth came from services and instrument sales rather than those back-ended payments, so investors may weigh whether this base is durable.

Analyst inference

What to watch

1. Watch whether service revenue keeps growing from more work on antibody and ion channel programs, since that work drove part of the third-quarter increase. Confirmed
2. The company's raised 2026 revenue guidance and cash outlook should be checked against actual fourth-quarter results to see if the improvement holds. Proposed
3. Progress on milestone- and royalty-bearing partnered programs matters because those payments could support revenue later, but timing and amounts remain uncertain for investors. Analyst inference

Evidence

• Original source link unavailable